Drug major Dr Reddy's Laboratories Limited's wholly owned subsidiary, Dr. Reddy's Laboratories SA, Switzerland, has received ...
Approvals expand Amneal’s biosimilars portfolioCompany expects to commercialize six biosimilars across eight presentations by 2027 BRIDGEWATER, N.J., Dec. 22, 2025 (GLOBE NEWSWIRE) -- Amneal ...
Bridgewater: Amneal Pharma and mAbxience, a Fresenius Kabi majority-owned group with partial ownership from Insud Pharma, ...
Amneal Pharma receives US FDA approval for denosumab biosimilars Prolia and Xgeva: Bridgewater, New Jersey Friday, December 26, 2025, 16:00 Hrs [IST] Bridgewater headquartered Amn ...
13d
Mabxience And Amneal Announces FDA Approval Of Denosumab Biosimilars Referencing Prolia® And XGEVA®
Mabxience And Amneal Announces FDA Approval Of Denosumab Biosimilars Referencing Prolia® And XGEVA®. mAbxience / Key word(s): Miscellaneous mAbxience and Amneal Announces FDA Approval of Denosumab ...
Pharmaceutical Technology on MSN
Samsung Bioepis initiates Byooviz commercialisation in Europe
Samsung Bioepis has started direct commercialisation of Byooviz, a biosimilar to Genentech’s Lucentis (ranibizumab), in ...
TipRanks on MSN
Dr. Reddy’s faces FDA setback on AVT03 denosumab biosimilar after manufacturing inspection
Dr Reddy’s Laboratories ( ($RDY) ) just unveiled an update. On December 31, 2025, Dr. Reddy’s Laboratories disclosed that its wholly owned Swiss ...
Approvals expand Amneal's biosimilars portfolioCompany expects to commercialize six biosimilars across eight presentations by 2027 BRIDGEWATER, N.J., Dec. 22, 2025 (GLOBE NEWSWIRE) -- Amneal Pharmaceu ...
Investing.com -- Amneal Pharmaceuticals Inc Class A (NASDAQ:AMRX) stock rose 2% in after-hours trading on Monday after the company announced FDA approval for two biosimilar drugs, expanding its ...
Dr Reddy's Laboratories announced that its wholly owned subsidiary, Dr. Reddy's Laboratories SA, Switzerland, has received a Complete Response Letter (CRL) from the USFDA for its Biologics License ...
AVT03 is a proposed biosimilar candidate to Prolia and Xgeva, developed by Alvotech hf. The application was submitted by Dr ...
Amneal Pharmaceuticals and mAbxience received Food and Drug Administration approval for two biosimilars. The companies said Monday that the FDA greenlit Biologics Licensing Applications for Boncresa, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback